PFESeagen, a wholly owned subsidiary of PfizerRunning, no new patients
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
HER2 Positive Breast Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 654 (final count)
- Started
- Mar 7, 2022
- Main results expected
- Sep 5, 2025
- Fully finished
- Sep 28, 2027
- Results posted
- Sep 29, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) as Assessed by Investigator Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1
Measured over: From randomization until the first documentation of PD or death from any cause or censoring date, whichever occurred first (maximum treatment exposure was of 41.3 months)
Changes Tremor has spotted
Paperwork edit (contacts, locations, wording). Usually harmless.
Spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- 2026-11-09 15:36 UTC · paperwork · other
old: null
new: null
details: {"sections":["referencesModule"]}
Trial ID NCT05132582 · record last updated 2026-09-29 · checked 2026-11-09 15:42 UTC